Modification of the pT2 substage classification in prostate adenocarcinoma

Mark Ettel, Max Kong, Peng Lee, Ming Zhou, Jonathan Melamed, Fang Ming Deng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The current substage classification of pT2 prostate cancer (AJCC, 7th edition, 2010) into pT2a (unilateral tumors < 1/2 of lobe), pT2b (unilateral tumors ≥ 1/2 of lobe), and pT2c (bilateral tumors) is of questionable relevance. Many studies show no difference in prognosis between substages, and incidence of pT2b prostate cancer is low. Other classification systems have been proposed based on tumor volume, as measured by dominant nodule size or tumor percentage. We characterized pT2b tumors and assessed the utility of current pT2 substaging in predicting biochemical recurrence–free survival after radical prostatectomy and compared them with different substaging methods based on tumor volume. Patients with pT2 tumors were selected among patients who underwent radical prostatectomy from 1998 to 2008. Dominant nodule size was dichotomized as < 1.6 cm versus ≥ 1.6 cm. Tumor percentage was dichotomized as ≤ 25% versus > 25%. Kaplan-Meier analysis and multivariate Cox proportional hazard regression models were used to evaluate pathological parameters predictive of biochemical recurrence–free survival. Of 785 patients who met criteria, 145 (18.5%) were pT2a, 15 (1.9%) were pT2b, and 625 (79.6%) were pT2c. The pT2 substages were not significant predictors of biochemical recurrence–free survival on univariate or multivariate analysis. In a multivariate model, tumor percentage > 25% (P = .002) was associated with decreased biochemical recurrence–free survival. In patients with stage pT2 prostate cancer, the current substaging method lacks predictive value for biochemical recurrence–free survival after accounting for other pathologic and clinical predictors. However, tumor percentage (≤ 25% versus > 25%) is a promising approach to substaging of pT2 prostate cancer based on its prognostic significance.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalHuman Pathology
Volume56
DOIs
StatePublished - Oct 1 2016

Fingerprint

Prostate
Adenocarcinoma
Prostatic Neoplasms
Survival
Neoplasms
Kaplan-Meier Estimate
Proportional Hazards Models
Multivariate Analysis

Keywords

  • Prognosis
  • Prostate adenocarcinoma
  • Radical prostatectomy
  • Recurrence-free survival
  • Staging

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ettel, M., Kong, M., Lee, P., Zhou, M., Melamed, J., & Deng, F. M. (2016). Modification of the pT2 substage classification in prostate adenocarcinoma. Human Pathology, 56, 57-63. https://doi.org/10.1016/j.humpath.2016.05.016

Modification of the pT2 substage classification in prostate adenocarcinoma. / Ettel, Mark; Kong, Max; Lee, Peng; Zhou, Ming; Melamed, Jonathan; Deng, Fang Ming.

In: Human Pathology, Vol. 56, 01.10.2016, p. 57-63.

Research output: Contribution to journalArticle

Ettel, M, Kong, M, Lee, P, Zhou, M, Melamed, J & Deng, FM 2016, 'Modification of the pT2 substage classification in prostate adenocarcinoma', Human Pathology, vol. 56, pp. 57-63. https://doi.org/10.1016/j.humpath.2016.05.016
Ettel, Mark ; Kong, Max ; Lee, Peng ; Zhou, Ming ; Melamed, Jonathan ; Deng, Fang Ming. / Modification of the pT2 substage classification in prostate adenocarcinoma. In: Human Pathology. 2016 ; Vol. 56. pp. 57-63.
@article{1db608199a804a3e904314cbb6ebc6e9,
title = "Modification of the pT2 substage classification in prostate adenocarcinoma",
abstract = "The current substage classification of pT2 prostate cancer (AJCC, 7th edition, 2010) into pT2a (unilateral tumors < 1/2 of lobe), pT2b (unilateral tumors ≥ 1/2 of lobe), and pT2c (bilateral tumors) is of questionable relevance. Many studies show no difference in prognosis between substages, and incidence of pT2b prostate cancer is low. Other classification systems have been proposed based on tumor volume, as measured by dominant nodule size or tumor percentage. We characterized pT2b tumors and assessed the utility of current pT2 substaging in predicting biochemical recurrence–free survival after radical prostatectomy and compared them with different substaging methods based on tumor volume. Patients with pT2 tumors were selected among patients who underwent radical prostatectomy from 1998 to 2008. Dominant nodule size was dichotomized as < 1.6 cm versus ≥ 1.6 cm. Tumor percentage was dichotomized as ≤ 25{\%} versus > 25{\%}. Kaplan-Meier analysis and multivariate Cox proportional hazard regression models were used to evaluate pathological parameters predictive of biochemical recurrence–free survival. Of 785 patients who met criteria, 145 (18.5{\%}) were pT2a, 15 (1.9{\%}) were pT2b, and 625 (79.6{\%}) were pT2c. The pT2 substages were not significant predictors of biochemical recurrence–free survival on univariate or multivariate analysis. In a multivariate model, tumor percentage > 25{\%} (P = .002) was associated with decreased biochemical recurrence–free survival. In patients with stage pT2 prostate cancer, the current substaging method lacks predictive value for biochemical recurrence–free survival after accounting for other pathologic and clinical predictors. However, tumor percentage (≤ 25{\%} versus > 25{\%}) is a promising approach to substaging of pT2 prostate cancer based on its prognostic significance.",
keywords = "Prognosis, Prostate adenocarcinoma, Radical prostatectomy, Recurrence-free survival, Staging",
author = "Mark Ettel and Max Kong and Peng Lee and Ming Zhou and Jonathan Melamed and Deng, {Fang Ming}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2016.05.016",
language = "English (US)",
volume = "56",
pages = "57--63",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Modification of the pT2 substage classification in prostate adenocarcinoma

AU - Ettel, Mark

AU - Kong, Max

AU - Lee, Peng

AU - Zhou, Ming

AU - Melamed, Jonathan

AU - Deng, Fang Ming

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The current substage classification of pT2 prostate cancer (AJCC, 7th edition, 2010) into pT2a (unilateral tumors < 1/2 of lobe), pT2b (unilateral tumors ≥ 1/2 of lobe), and pT2c (bilateral tumors) is of questionable relevance. Many studies show no difference in prognosis between substages, and incidence of pT2b prostate cancer is low. Other classification systems have been proposed based on tumor volume, as measured by dominant nodule size or tumor percentage. We characterized pT2b tumors and assessed the utility of current pT2 substaging in predicting biochemical recurrence–free survival after radical prostatectomy and compared them with different substaging methods based on tumor volume. Patients with pT2 tumors were selected among patients who underwent radical prostatectomy from 1998 to 2008. Dominant nodule size was dichotomized as < 1.6 cm versus ≥ 1.6 cm. Tumor percentage was dichotomized as ≤ 25% versus > 25%. Kaplan-Meier analysis and multivariate Cox proportional hazard regression models were used to evaluate pathological parameters predictive of biochemical recurrence–free survival. Of 785 patients who met criteria, 145 (18.5%) were pT2a, 15 (1.9%) were pT2b, and 625 (79.6%) were pT2c. The pT2 substages were not significant predictors of biochemical recurrence–free survival on univariate or multivariate analysis. In a multivariate model, tumor percentage > 25% (P = .002) was associated with decreased biochemical recurrence–free survival. In patients with stage pT2 prostate cancer, the current substaging method lacks predictive value for biochemical recurrence–free survival after accounting for other pathologic and clinical predictors. However, tumor percentage (≤ 25% versus > 25%) is a promising approach to substaging of pT2 prostate cancer based on its prognostic significance.

AB - The current substage classification of pT2 prostate cancer (AJCC, 7th edition, 2010) into pT2a (unilateral tumors < 1/2 of lobe), pT2b (unilateral tumors ≥ 1/2 of lobe), and pT2c (bilateral tumors) is of questionable relevance. Many studies show no difference in prognosis between substages, and incidence of pT2b prostate cancer is low. Other classification systems have been proposed based on tumor volume, as measured by dominant nodule size or tumor percentage. We characterized pT2b tumors and assessed the utility of current pT2 substaging in predicting biochemical recurrence–free survival after radical prostatectomy and compared them with different substaging methods based on tumor volume. Patients with pT2 tumors were selected among patients who underwent radical prostatectomy from 1998 to 2008. Dominant nodule size was dichotomized as < 1.6 cm versus ≥ 1.6 cm. Tumor percentage was dichotomized as ≤ 25% versus > 25%. Kaplan-Meier analysis and multivariate Cox proportional hazard regression models were used to evaluate pathological parameters predictive of biochemical recurrence–free survival. Of 785 patients who met criteria, 145 (18.5%) were pT2a, 15 (1.9%) were pT2b, and 625 (79.6%) were pT2c. The pT2 substages were not significant predictors of biochemical recurrence–free survival on univariate or multivariate analysis. In a multivariate model, tumor percentage > 25% (P = .002) was associated with decreased biochemical recurrence–free survival. In patients with stage pT2 prostate cancer, the current substaging method lacks predictive value for biochemical recurrence–free survival after accounting for other pathologic and clinical predictors. However, tumor percentage (≤ 25% versus > 25%) is a promising approach to substaging of pT2 prostate cancer based on its prognostic significance.

KW - Prognosis

KW - Prostate adenocarcinoma

KW - Radical prostatectomy

KW - Recurrence-free survival

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=84979518485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979518485&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.05.016

DO - 10.1016/j.humpath.2016.05.016

M3 - Article

C2 - 27251951

AN - SCOPUS:84979518485

VL - 56

SP - 57

EP - 63

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -